Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360684" target="_blank" >RIV/00216208:11110/17:10360684 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/17:10360684 RIV/00064203:_____/17:10360684
Result on the web
<a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171539" target="_blank" >http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171539</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1371/journal.pone.0171539" target="_blank" >10.1371/journal.pone.0171539</a>
Alternative languages
Result language
angličtina
Original language name
Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
Original language description
High hydrostatic pressure (HHP) induces immunogenic death of tumor cells which confer protective anti-tumor immunity in vivo. Moreover, DC pulsed with HHP-treated tumor cells induced therapeutic effect in mouse cancer model. In this study, we tested the immunogenicity, stability and T cell stimulatory activity of human monocyte-derived dendritic cell (DC)based HHP lung cancer vaccine generated in GMP compliant serum free medium using HHP 250 MPa. DC pulsed with HHP-killed lung cancer cells and poly(I:C) enhanced DC maturation, chemotactic migration and production of pro-inflammatory cytokines after 24h. Moreover, DC-based HHP lung cancer vaccine showed functional plasticity after transfer into serum-containing media and stimulation with LPS or CD40L after additional 24h. LPS and CD40L stimulation further differentially enhanced the expression of costimulatory molecules and production of IL-12p70. DC-based HHP lung cancer vaccine decreased the number of CD4(+) CD25(+) Foxp3(+) T regulatory cells and stimulated IFN-gamma-producing tumor antigenspecific CD4(+) and CD8(+) T cells from non-small cell lung cancer (NSCLC) patients. Tumor antigen specific CD8(+) and CD4(+) T cell responses were detected in NSCLC patient's against a selected tumor antigens expressed by lung cancer cell lines used for the vaccine generation. We also showed for the first time that protein antigen from HHP-killed lung cancer cells is processed and presented by DC to CD8(+) T cells. Our results represent important preclinical data for ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa) in combination with chemotherapy and immune enhancers.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
PLoS One
ISSN
1932-6203
e-ISSN
—
Volume of the periodical
12
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
18
Pages from-to
—
UT code for WoS article
000394244300028
EID of the result in the Scopus database
2-s2.0-85012123599